Tidal Investments LLC Boosts Stake in IQVIA Holdings Inc. (NYSE:IQV)

Tidal Investments LLC lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 9.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 5,980 shares of the medical research company’s stock after purchasing an additional 509 shares during the quarter. Tidal Investments LLC’s holdings in IQVIA were worth $1,417,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB purchased a new stake in shares of IQVIA during the third quarter valued at about $2,310,000. Arvest Bank Trust Division purchased a new stake in IQVIA during the third quarter valued at approximately $21,079,000. World Investment Advisors LLC acquired a new stake in IQVIA in the third quarter valued at approximately $14,633,000. Sanctuary Advisors LLC increased its position in shares of IQVIA by 60.8% during the third quarter. Sanctuary Advisors LLC now owns 5,498 shares of the medical research company’s stock worth $1,303,000 after purchasing an additional 2,079 shares in the last quarter. Finally, Pine Valley Investments Ltd Liability Co lifted its holdings in shares of IQVIA by 0.5% during the 3rd quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock valued at $2,247,000 after purchasing an additional 50 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of NYSE IQV opened at $190.97 on Thursday. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company’s fifty day moving average price is $210.32 and its 200 day moving average price is $223.64. The company has a market capitalization of $34.66 billion, a PE ratio of 25.06, a price-to-earnings-growth ratio of 2.05 and a beta of 1.49.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. The Goldman Sachs Group decreased their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Barclays dropped their target price on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Truist Financial decreased their price target on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft cut their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Redburn Atlantic initiated coverage on IQVIA in a research report on Monday, October 14th. They set a “buy” rating and a $276.00 price target for the company. Four research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $256.19.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.